215 related articles for article (PubMed ID: 12084163)
21. Quality and clinical response to transfusion of prestorage white cell-reduced apheresis platelets prepared by use of an in-line white cell-reduction system.
Elfath M; Tahhan H; Mintz P; Dumont L; Whitley P; Sawyer S; McNeil D
Transfusion; 1999 Sep; 39(9):960-6. PubMed ID: 10533822
[TBL] [Abstract][Full Text] [Related]
22. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction.
Paglino JC; Pomper GJ; Fisch GS; Champion MH; Snyder EL
Transfusion; 2004 Jan; 44(1):16-24. PubMed ID: 14692962
[TBL] [Abstract][Full Text] [Related]
23. Trend towards reduction of transfusion reactions using prestorage leukocyte-reduced and pooled whole blood-derived platelets and cost savings compared with poststorage whole blood-derived random platelets as evidenced by real-time hemovigilance.
Park N; Correa Medina M; Martinez F; Throssel M; Dasgupta A; Knopfelmacher A; Villamin C; Rivas S; Tomczak N; Garg S; Layton L; Klein K
Lab Med; 2024 May; 55(3):251-254. PubMed ID: 38175635
[TBL] [Abstract][Full Text] [Related]
24. Febrile nonhemolytic transfusion reactions to platelets.
Heddle NM
Curr Opin Hematol; 1995 Nov; 2(6):478-83. PubMed ID: 9372039
[TBL] [Abstract][Full Text] [Related]
25. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
[TBL] [Abstract][Full Text] [Related]
26. Providing leukocyte-reduced platelets using the CS-3000 PLUS.
Abreu ED; Strauss RG; Cordle DG; Kingery LR; Ludwig GA; Randels MJ
J Clin Apher; 1996; 11(1):27-9. PubMed ID: 8722719
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a whole-blood WBC-reduction filter that saves platelets: in vitro studies.
Larsson S; Gulliksson H; Paunovic D
Transfusion; 2001 Apr; 41(4):534-9. PubMed ID: 11316906
[TBL] [Abstract][Full Text] [Related]
28. The utility of < or =3-day-old whole-blood platelets in reducing the incidence of febrile nonhemolytic transfusion reactions.
Kelley DL; Mangini J; Lopez-Plaza I; Triulzi DJ
Transfusion; 2000 Apr; 40(4):439-42. PubMed ID: 10773056
[TBL] [Abstract][Full Text] [Related]
29. WBC reduction in RBC concentrates by prestorage filtration: multicenter experience.
Yomtovian R; Gernsheimer T; Assmann SF; Mohandas K; Lee TH; Kalish LA; Busch MP;
Transfusion; 2001 Aug; 41(8):1030-6. PubMed ID: 11493735
[TBL] [Abstract][Full Text] [Related]
30. Leucocyte and platelet-derived bioactive substances in stored blood: effect of prestorage leucocyte filtration.
Nielsen HJ; Skov F; Dybkjaer E; Reimert CM; Pedersen AN; Brünner N; Skov PS
Eur J Haematol; 1997 Apr; 58(4):273-8. PubMed ID: 9186539
[TBL] [Abstract][Full Text] [Related]
31. Analysis of transfusion reactions associated with prestorage-pooled platelet components.
Tormey CA; Sweeney JD; Champion MH; Pisciotto PT; Snyder EL; Wu Y
Transfusion; 2009 Jun; 49(6):1242-7. PubMed ID: 19389029
[TBL] [Abstract][Full Text] [Related]
32. Signs and symptoms associated with the transfusion of WBC-reduced RBCs and non-WBC-reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study.
Lane TA; Gernsheimer T; Mohandas K; Assmann SF
Transfusion; 2002 Feb; 42(2):265-74. PubMed ID: 11896345
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial.
Enright H; Davis K; Gernsheimer T; McCullough JJ; Woodson R; Slichter SJ
Transfusion; 2003 Nov; 43(11):1545-52. PubMed ID: 14617313
[TBL] [Abstract][Full Text] [Related]
34. White cell-reduced platelet concentrates prepared by in-line filtration of platelet-rich plasma.
Sweeney JD; Holme S; Heaton WA; Nelson E
Transfusion; 1995 Feb; 35(2):131-6. PubMed ID: 7825208
[TBL] [Abstract][Full Text] [Related]
35. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study.
de Wildt-Eggen J; Nauta S; Schrijver JG; van Marwijk Kooy M; Bins M; van Prooijen HC
Transfusion; 2000 Apr; 40(4):398-403. PubMed ID: 10773049
[TBL] [Abstract][Full Text] [Related]
36. Effects of filtration and gamma radiation on the accumulation of RANTES and transforming growth factor-beta1 in apheresis platelet concentrates during storage.
Fujihara M; Ikebuchi K; Wakamoto S; Sekiguchi S
Transfusion; 1999 May; 39(5):498-505. PubMed ID: 10336000
[TBL] [Abstract][Full Text] [Related]
37. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans.
Stohlawetz P; Horvath M; Pernerstorfer T; Nguyen H; Vondrovec B; Robisch A; Eichler HG; Spitzauer S; Jilma B
Transfusion; 1999 May; 39(5):506-14. PubMed ID: 10336001
[TBL] [Abstract][Full Text] [Related]
38. Reactions to platelet transfusion: the effect of the storage time of the concentrate.
Muylle L; Wouters E; De Bock R; Peetermans ME
Transfus Med; 1992 Dec; 2(4):289-93. PubMed ID: 1339583
[TBL] [Abstract][Full Text] [Related]
39. Transfusion of platelet concentrates from pooled buffy-coats: comparison of bedside vs. prestorage leukofiltration.
Müller-Steinhardt M; Schlenke P; Wagner T; Klüter H
Transfus Med; 2000 Mar; 10(1):59-65. PubMed ID: 10760204
[TBL] [Abstract][Full Text] [Related]
40. Binding of activated platelets to WBCs in vivo after transfusion.
Gutensohn K; Geidel K; Brockmann M; Siemensen M; Krueger W; Kroeger N; Kuehnl P
Transfusion; 2002 Oct; 42(10):1373-80. PubMed ID: 12423523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
